Allianz SE Takes Position in Stevanato Group S.p.A. (NYSE:STVN)

Allianz SE acquired a new stake in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 34,690 shares of the company's stock, valued at approximately $748,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Blair William & Co. IL bought a new stake in shares of Stevanato Group during the 4th quarter valued at $466,000. Artisan Partners Limited Partnership grew its holdings in Stevanato Group by 28.7% in the fourth quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company's stock worth $51,333,000 after purchasing an additional 524,989 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Stevanato Group by 34.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 19,358 shares of the company's stock worth $458,000 after purchasing an additional 4,976 shares during the period. Pier Capital LLC increased its stake in shares of Stevanato Group by 2.9% during the fourth quarter. Pier Capital LLC now owns 381,624 shares of the company's stock valued at $8,316,000 after purchasing an additional 10,627 shares in the last quarter. Finally, Zions Bancorporation N.A. lifted its holdings in shares of Stevanato Group by 29.7% during the fourth quarter. Zions Bancorporation N.A. now owns 68,017 shares of the company's stock valued at $1,482,000 after purchasing an additional 15,555 shares during the last quarter.

Wall Street Analysts Forecast Growth

STVN has been the subject of a number of analyst reports. Wolfe Research started coverage on Stevanato Group in a research report on Friday, December 13th. They set an "outperform" rating and a $28.00 price objective for the company. Bank of America lifted their price target on Stevanato Group from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. William Blair reissued an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th. Finally, UBS Group reduced their price objective on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of €25.70 ($28.24).

Remove Ads

Stevanato Group Stock Performance

Shares of Stevanato Group stock traded down €1.08 ($1.19) during trading on Friday, hitting €19.01 ($20.89). 404,700 shares of the company's stock traded hands, compared to its average volume of 352,794. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.20) and a 1 year high of €30.10 ($33.08). The business has a 50-day simple moving average of €20.74 and a 200-day simple moving average of €20.61. The stock has a market capitalization of $5.76 billion, a P/E ratio of 40.45, a PEG ratio of 7.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, hitting analysts' consensus estimates of €0.20 ($0.22). The firm had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. As a group, analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.